MediPoint: Peripheral Vascular Stents for the Lower Extremity - EU Analysis and Market Forecasts

NEW YORK, May 27, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

MediPoint: Peripheral Vascular Stents for the Lower Extremity - EU Analysis and Market Forecasts
http://www.reportlinker.com/p01190438/MediPoint-Peripheral-Vascular-Stents-for-the-Lower-Extremity---EU-Analysis-and-Market-Forecasts.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Surgical_Equipment

MediPoint: Peripheral Vascular Stents for the Lower Extremity - EU Analysis and Market Forecasts

Summary

Endovascular therapies such as stenting have been widely adopted to treat peripheral artery disease (PAD) in the lower extremity. Peripheral vascular stents including bare metal, drug-eluting, covered and bioabsorbable stents are associated with improved clinical outcomes compared to balloon angioplasty alone. The global peripheral vascular stent (PVS) market is steadily growing in the 10 countries covered in the report, including the US, France, Germany, Italy, Spain, UK, Japan, Brazil, China and India. Through GlobalData's analysis, it is evident that currently the peripheral vascular stent market for the lower extremity is saturated with bare metal stents, followed by covered stents. However, as clinical data and appropriate reimbursement and costs are established, adoption of innovative stent technologies such as drug-eluting stents and bioabsorbable stents will increase in the future.

The peripheral vascular stent market is a large and dynamic one that allows stent manufacturers to develop different types of vascular stent platforms for different types of arteries in the lower extremity. As PAD presents enormous global public health and socioeconomic issues, it is pertinent to find effective treatment modalities that ensure long-term quality results for patients. This report looks at the current peripheral vascular stent market for the lower extremity in the five EU countries and evaluates the adoption and opportunities for this technology in these markets.

Scope

- An overview of PAD, which includes epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines.
- Annualized EU PVS market revenue and future forecasts from 2009 to 2011, forecast for 7 years to 2018.
- Investigation of current and future market competition for PVS
- Insightful review of the key industry drivers, restraints and challenges as well as predicted impact of key events.
- Competitor assessment including device approval analysis and device sales forecasts.
- Marketed and pipeline product profiles covering efficiency, safety, clinical study details, device approvals, product positioning and device sales forecast.
- Analysis of unmet needs within the market and opportunities for future players.
- Technology trends evaluation to assess strength of pipeline.
- An overview of all devices in development including clinical study details, design and material selection considerations, efficacy reports, and device approval timelines.
- Company profiles including business description, financial overview and SWOT analysis.
- Coverage of key market players.
- Strategic assessment of the PVS sector through market impact analysis, future market scenario and company analysis.
- Direct quotes from Key Opinion Leaders (KOL) as well as cardiologists

Reasons to buy

- Understand the trends shaping and driving EU PVS Market.
- Realize device preferences of physicians who have performed the tests already.
- Access market sizing, forecasts and quantified growth opportunities in the US PVS Market through 2018.
- Quantify candidate patient populations to better design product pricing & launch plans.
- Drive revenues, formulate effective sales and marketing strategies and gain in-depth understanding of the competitive landscape.
- Perform benchmarking analysis of growth opportunities against currently marketed products.
- Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
- Take a comprehensive look at the market's device pipeline and identify promising, paradigm-shifting products.
- Create an effective counter-strategy to gain a competitive advantage against those currently in the market.
- Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for growth.
- What's the next big thing in EU PVS market landscape? Identify, understand and capitalize.

Table of Contents

1 Table of Contents 7
1.1 List of Tables 15
1.2 List of Figures 23
2 Introduction 25
2.1 Catalyst 26
2.2 Related Reports 26
3 Peripheral Artery Disease 27
3.1 Overview 27
3.2 Anatomy and Physiology 28
3.2.1 Peripheral Arteries of the Lower Extremity 28
3.3 Pathophysiology 30
3.4 Clinical Presentation 31
3.4.1 Symptoms of Peripheral Artery Disease 31
3.4.2 Risk Factors 33
3.4.3 Disease Classification 33
3.4.4 Diagnosis 34
3.5 Clinical Outcomes 36
3.5.1 Treatment Paradigm 36
3.5.2 Treatment Guidelines 36
3.5.3 Treatment Modalities 40
3.5.4 Endovascular Management of PAD 54
3.6 Epidemiology 58
3.6.1 Peripheral Artery Disease 58
3.7 Economic Impact 61
3.7.1 EU 62
3.8 Treatment Costs 63
4 Competitive Assessment 65
4.1 Overview 65
4.1.1 Peripheral Vascular Stent Market 65
4.2 Products 68
4.2.1 Bare Metal Stents 68
4.2.2 Drug-Eluting Stents 153
4.2.3 Covered Stents 160
4.2.4 Bioabsorbable Stents 171
5 Unmet Needs 174
5.1 Need for Better Clinical Outcomes in Specific Lesions 174
5.1.1 Chronic Total Occlusions 174
5.1.2 Long Lesions 174
5.1.3 Heavily-Calcified and Uncrossable Lesions 175
5.1.4 Bifurcation Lesions 175
5.2 Need to Improve Medical Therapy 176
5.3 Comparative Studies on Exercise Therapy 176
5.4 Addressing Complications of Lower-Extremity Bypass Surgery 177
5.5 Eliminating Mechanisms of Failure with Balloon Angioplasty 177
5.6 Need for Better Revascularization of the Femoropopliteal Artery 178
5.7 Difficulty in Treating the Infrapopliteal Artery 179
5.8 Lack of Clinical Data 179
5.9 Limited Designs of Low-Profile Devices 180
5.10 Addressing Challenges of Peripheral Stenting 181
5.10.1 Risk of Post-Procedural Complications 181
5.10.2 In-Stent Restenosis 182
5.10.3 Stent Fracture 182
5.10.4 Long-Term Vessel Patency 183
5.10.5 Stent Material 183
5.10.6 Stent Deployment and Deliverability 184
5.10.7 Dual Anti-Platelet Therapy 185
5.10.8 Imaging 185
6 Pipeline Products 186
6.1 Overview 186
6.2 Pipeline by Phase of Development 187
6.3 Pipeline Product Profiles – Peripheral Artery Disease 189
6.3.1 Citation Stent 189
6.3.2 MR-Enhanced Stents 190
6.3.3 ArtiStent 191
6.3.4 Hybrid Dynamic Stent 191
6.3.5 Nipro Corporation Peripheral Stent 191
6.3.6 Yukon 191
6.3.7 iCAST 193
6.3.8 Peritoneal-Lined Stents 194
6.3.9 LifeJacket Stent Graft 195
6.3.10 Esprit Bioabsorbable Vascular Scaffold (BVS) 196
6.3.11 Magic Explorer Stent 198
6.3.12 Stanza 200
6.3.13 3D Biotek Bioresorbable Stent 202
6.3.14 Archer Stent 203
6.3.15 ART Stent 204
6.3.16 Amaranth Bioabsorbable Scaffold 204
6.3.17 TephaFLEX Absorbable Peripheral Stent 204
6.3.18 Zorion Medical Stent 205
6.3.19 Summary 205
7 Clinical Trial Analysis 206
7.1 Overview 206
7.2 Trials to Watch 207
7.2.1 Abbott Vascular 207
7.2.2 Atrium Medical Corporation 208
7.2.3 Biotronik 209
7.2.4 480 Biomedical 209
7.2.5 Cook Medical 210
7.2.6 Covidien 211
7.2.7 Flexible Stenting Solutions 212
7.2.8 IDEV Technologies 213
7.2.9 Medtronic 214
7.2.10 Terumo Medical Corporation 215
8 Industry Overview 216
8.1 Procedure Trends 216
8.1.1 Factors Contributing to Rise of Peripheral Interventions 216
8.1.2 EU 217
8.2 Market Access 219
8.2.1 EU 219
8.3 Reimbursement Trends 223
8.3.1 EU 223
8.4 Regulatory Issues/Recalls 226
8.4.1 Regulatory Issues 226
8.4.2 Recalls 226
8.5 Mergers and Acquisitions 228
8.5.1 Abbott Laboratories 228
8.5.2 Atrium Medical Corporation 229
8.5.3 Boston Scientific Corporation 229
8.5.4 Cordis Corporation (Johnson & Johnson) 229
8.5.5 Covidien 230
8.5.6 CR Bard 230
8.5.7 Medtronic 230
8.5.8 Nexeon Stent 231
8.5.9 Terumo Corporation 231
9 Current and Future Players 232
9.1 Overview 232
9.2 Trends in Corporate Strategy 233
9.3 Company Profiles 236
9.3.1 Abbott Vascular 236
9.3.2 Amaranth Medical 238
9.3.3 Arterial Remodeling Technologies 240
9.3.4 Atrium Medical Corporation 242
9.3.5 Bard Peripheral Vascular (C.R. Bard) 244
9.3.6 Biotronik 246
9.3.7 Boston Scientific Corporation 248
9.3.8 3D Biotek 250
9.3.9 480 Biomedical 252
9.3.10 Cook Medical 254
9.3.11 Cordis Corporation (Johnson & Johnson) 256
9.3.12 CorInnova 258
9.3.13 Covidien 260
9.3.14 Cytograft Tissue Engineering 262
9.3.15 Flexible Stenting Solutions 264
9.3.16 IDEV Technologies 266
9.3.17 Kyoto Medical Planning 268
9.3.18 Medtronic 271
9.3.19 Nexeon Stent 273
9.3.20 Nipro Corporation 275
9.3.21 NovoStent Corporation 277
9.3.22 OptiMed 279
9.3.23 PeriTec Biosciences 281
9.3.24 Synergy Flow 283
9.3.25 Tepha 285
9.3.26 Terumo Corporation 287
9.3.27 TissueGen 289
9.3.28 Translumina 291
9.3.29 Vascular Concepts 293
9.3.30 Veryan Medical 295
9.3.31 VueKlar Cardiovascular 297
9.3.32 W.L. Gore & Associates 299
9.3.33 Zorion Medical 301
10 Market Drivers, Opportunities and Barriers 303
10.1 Market Drivers 303
10.1.1 Rising Prevalence of Disease 304
10.1.2 Long-Term Vessel Patency 305
10.1.3 Reducing the Risk of Restenosis 306
10.1.4 Low-Profile Stent System 307
10.1.5 Self-Expanding Nitinol Stents 308
10.1.6 Limb Amputation 309
10.1.7 Cost Considerations 309
10.1.8 Availability of Long-Term Data 310
10.1.9 Avoiding Stent-in-Stent Procedures 311
10.1.10 Reducing the Need for Dual Anti-Platelet Therapy 311
10.1.11 Accurate Stent Placement 311
10.1.12 Expected Launch of Vascular Stent Products in the US 312
10.2 Opportunities 313
10.2.1 Peripheral Stent Market 313
10.2.2 Challenges in Treating the Femoropopliteal and Infrapopliteal Arteries 315
10.2.3 Biodegradable and Bioabsorbable Stents 316
10.2.4 Target High-Risk Patients 316
10.2.5 Launch Vascular Stents in the Japanese Market 317
10.2.6 Emerging Markets 317
10.3 Market Barriers 318
10.3.1 Slow Adoption 318
10.3.2 High Selling Prices 322
10.3.3 Lack of Reimbursement 322
10.3.4 Substitutes 323
11 Country Outlooks and Forecasts 324
11.1 Overview 324
11.2 France 326
11.2.1 Overview 326
11.2.2 Market Analysis 326
11.3 Germany 329
11.3.1 Overview 329
11.3.2 Market Analysis 329
11.4 Italy 332
11.4.1 Overview 332
11.4.2 Market Analysis 332
11.5 Spain 334
11.5.1 Overview 334
11.5.2 Market Analysis 334
11.6 United Kingdom 337
11.6.1 Overview 337
11.6.2 Market Analysis 337
12 Appendix 340
12.1 Bibliography 340
12.2 Abbreviations 360
12.3 Report Methodology 363
12.3.1 Overview 363
12.3.2 Coverage 363
12.3.3 Secondary Research 363
12.3.4 Forecasting Methodology 364
12.4 Physicians and Specialists Included in this Study 365
12.5 Physician Survey 367
12.6 About the Authors 368
12.6.1 Analysts 368
12.6.2 Global Head of Healthcare 369
12.7 About MediPoint 369
12.8 About GlobalData 369
12.9 Contact Us 370
12.10 Disclaimer 370

List of Tables

Table 1: Classification Systems for Determining the Severity of PAD Symptoms 31
Table 2: Risk Factors Associated with Peripheral Artery Disease 33
Table 3: Types of Atherosclerotic Lesions 34
Table 4: TASC II Classification of Iliac Artery Lesions 37
Table 5: TASC II Classification of Femoropopliteal Artery Lesions 38
Table 6: TASC II Classification of Infrapopliteal Artery Lesions 39
Table 7: Complications of Peripheral Artery Bypass Surgery 44
Table 8: Drugs Incorporated Into Drug-Eluting Stents 47
Table 9: Types of Lesions Treated Using Atherectomy 50
Table 10: Prevalence of PAD in Population Age ?65 Years in the Major Markets in the EU, millions, 2010-2019 59
Table 11: Direct and Indirect Healthcare Costs 61
Table 12: Healthcare Expenditures* ($bn) for PAD in EU 62
Table 13: US Mean Hospital Costs* for Peripheral Revascularization Procedures, 2011–2018 ($US) 63
Table 14: EU* Peripheral Vascular Stent Market ($m) for Each Type of Artery in the Lower Extremity, 2012 66
Table 15: Marketed Bare Metal Stent Products 68
Table 16: Absolute Stent Family Product Portfolio 70
Table 17: Absolute Stent SWOT Analysis, 2013 73
Table 18: Astron Stent Product Portfolio 75
Table 19: Astron Stent SWOT Analysis, 2013 76
Table 20: BioMimics 3D Stent Product Portfolio 77
Table 21: BioMimics 3D Stent SWOT Analysis, 2013 78
Table 22: Complete Stent SE Product Portfolio 79
Table 23: Complete SE Stent SWOT Analysis, 2013 82
Table 24: E-Luminexx Stent Product Portfolio 83
Table 25: E-Luminexx Stent SWOT Analysis, 2013 84
Table 26: Epic Stent Product Portfolio 85
Table 27: Epic Stent SWOT Analysis, 2013 87
Table 28: FlexStent Iliac Stent System Product Portfolio 88
Table 29: FlexStent Iliac Stent System SWOT Analysis, 2013 89
Table 30: LifeStent Vascular Stent System Product Portfolio 90
Table 31: LifeStent Vascular Stent System SWOT Analysis, 2013 93
Table 32: Maris Deep Stent Product Portfolio 94
Table 33: Maris Deep Stent SWOT Analysis, 2013 95
Table 34: Maris Plus Stent Product Portfolio 96
Table 35: Maris Plus Stent SWOT Analysis, 2013 97
Table 36: Misago Stent Product Portfolio 98
Table 37: Misago Stent SWOT Analysis, 2013 100
Table 38: NovoStent Samba Stent System Product Portfolio 101
Table 39: NovoStent Samba Stent System SWOT Analysis, 2013 103
Table 40: Protégé Family of Stents Product Portfolio 104
Table 41: Protégé Family of Stents SWOT Analysis, 2013 106
Table 42: Pulsar 18 Stent Product Portfolio 107
Table 43: Pulsar 18 Stent SWOT Analysis, 2013 108
Table 44: SMART Stent Product Portfolio 109
Table 45: SMART Stent SWOT Analysis, 2013 111
Table 46: Sinus Stent Family Product Portfolio 112
Table 47: Sinus Stent Family SWOT Analysis, 2013 114
Table 48: Supera Veritas Stent Product Portfolio 115
Table 49: Supera Veritas Stent SWOT Analysis, 2013 118
Table 50: Wallstent Product Portfolio 119
Table 51: Wallstent SWOT Analysis, 2013 120
Table 52: Xpert Stent Product Portfolio 121
Table 53: Xpert Stent SWOT Analysis, 2013 124
Table 54: Zilver Stent Product Portfolio 125
Table 55: Zilver Stent SWOT Analysis, 2013 128
Table 56: Assurant Cobalt Stent Product Portfolio 129
Table 57: Assurant Cobalt Stent SWOT Analysis, 2013 131
Table 58: Chromis Deep Stent Product Portfolio 132
Table 59: Chromis Deep Stent SWOT Analysis, 2013 134
Table 60: Dynamic Stent Product Portfolio 135
Table 61: Dynamic Stent SWOT Analysis, 2013 136
Table 62: Express LD Product Portfolio 137
Table 63: Express LD SWOT Analysis, 2013 139
Table 64: IntraStent LD Stent Product Portfolio 140
Table 65: IntraStent LD Stent SWOT Analysis, 2013 141
Table 66: Omnilink Elite Stent Product Portfolio 142
Table 67: Omnilink Elite Stent SWOT Analysis, 2013 144
Table 68: ParaMount Mini GPS Product Portfolio 145
Table 69: ParaMount Mini GPS SWOT Analysis, 2013 146
Table 70: ProStar Stent Product Portfolio 147
Table 71: ProStar Stent SWOT Analysis, 2013 148
Table 72: Scuba Stent Product Portfolio 149
Table 73: Scuba Stent SWOT Analysis, 2013 150
Table 74: Visi-Pro Stent Product Portfolio 151
Table 75: Visi-Pro Stent SWOT Analysis, 2013 152
Table 76: Marketed Drug-Eluting Stent Products 153
Table 77: Xience Prime BTK Stent Product Portfolio 153
Table 78: Xience Prime BTK Stent SWOT Analysis, 2013 155
Table 79: Zilver PTX Stent Product Portfolio 156
Table 80: Zilver PTX Stent SWOT Analysis, 2013 159
Table 81: Marketed Covered Stent Products 160
Table 82: Gore Viabahn Stent Product Portfolio 161
Table 83: Gore Viabahn Stent SWOT Analysis, 2013 164
Table 84: Gore Tigris Stent Product Portfolio 165
Table 85: Gore Tigris Stent SWOT Analysis, 2013 167
Table 86: V12 Covered Stents Product Portfolio 168
Table 87: V12 Covered Stents SWOT Analysis, 2013 170
Table 88: Remedy Stent Product Portfolio 171
Table 89: Remedy Stent SWOT Analysis, 2012 173
Table 90: Global Peripheral Vascular Stent Product Pipeline 188
Table 91: Citation Stent SWOT Analysis, 2013 189
Table 92: MR-Enhanced Stents SWOT Analysis, 2013 190
Table 93: Yukon Stent SWOT Analysis, 2013 192
Table 94: iCAST Stent SWOT Analysis, 2013 194
Table 95: Peritoneal-Lined Stents SWOT Analysis, 2013 195
Table 96: Esprit BVS SWOT Analysis, 2013 197
Table 97: Magic Explorer Stent SWOT Analysis, 2013 199
Table 98: Stanza Stent SWOT Analysis, 2013 201
Table 99: 3D Biotek Bioresorbable Stent SWOT Analysis, 2013 202
Table 100: Archer Stent SWOT Analysis, 2013 203
Table 101: Abbott Vascular Company Profile 236
Table 102: Abbott Vascular, Marketed and Pipeline Vascular Stent Products 237
Table 103: Abbott Vascular SWOT Analysis, 2013 237
Table 104: Amaranth Medical Company Profile 238
Table 105: Amaranth Medical, Pipeline Vascular Stent Products 239
Table 106: Amaranth Medical SWOT Analysis, 2013 239
Table 107: Arterial Remodeling Technologies Company Profile 240
Table 108: Arterial Remodeling Technologies' Pipeline Vascular Stent Products 241
Table 109: Arterial Remodeling Technologies SWOT Analysis, 2013 241
Table 110: Atrium Medical Corporation Company Profile 242
Table 111: Atrium Medical Corporation, Marketed and Pipeline Vascular Stent Products 243
Table 112: Atrium Medical Corporation SWOT Analysis, 2013 243
Table 113: Bard Peripheral Vascular (C.R. Bard) Company Profile 244
Table 114: Bard Peripheral Vascular (C.R. Bard), Marketed Stent Products 245
Table 115: Bard Peripheral Vascular (C.R. Bard) SWOT Analysis, 2013 245
Table 116: Biotronik Company Profile 246
Table 117: Marketed and Pipeline Vascular Stent Products by Biotronik 247
Table 118: Biotronik SWOT Analysis, 2013 247
Table 119: Boston Scientific Corporation Company Profile 248
Table 120: Boston Scientific Corporation, Marketed and Pipeline Vascular Stent Products 249
Table 121: Boston Scientific Corporation SWOT Analysis, 2013 249
Table 122: Company Profile – 3D Biotek 250
Table 123: 3D Biotek's Pipeline Vascular Stent Products 251
Table 124: 3D Biotek SWOT Analysis, 2013 251
Table 125: 480 Biomedical Company Profile 252
Table 126: 480 Biomedical, Pipeline Vascular Stent Products 253
Table 127: 480 Biomedical SWOT Analysis, 2013 253
Table 128: Cook Medical Company Profile 254
Table 129: Cook Medical, Marketed Vascular Stent Products 255
Table 130: Cook Medical SWOT Analysis, 2013 255
Table 131: Cordis Corporation Company Profile 256
Table 132: Cordis Corporation's Marketed Vascular Stent Products 257
Table 133: Cordis Corporation SWOT Analysis, 2013 257
Table 134: CorInnova Company Profile 258
Table 135: CorInnova, Pipeline Vascular Stent Products 258
Table 136: CorInnova SWOT Analysis, 2013 259
Table 137: Covidien Company Profile 260
Table 138: Covidien's Marketed Vascular Stent Products 261
Table 139: Covidien SWOT Analysis, 2013 261
Table 140: Company Profile – Cytograft Tissue Engineering 262
Table 141: Cytograft Tissue Engineering, Pipeline Vascular Stent Products 263
Table 142: Cytograft Tissue Engineering SWOT Analysis, 2013 263
Table 143: Flexible Stenting Solutions Company Profile 264
Table 144: Flexible Stenting Solutions' Marketed Vascular Stent Products 265
Table 145: Flexible Stenting Solutions SWOT Analysis, 2013 265
Table 146: IDEV Technologies Company Profile 266
Table 147: IDEV Technologies' Marketed Vascular Stent Products 267
Table 148: IDEV Technologies SWOT Analysis, 2013 267
Table 149: Kyoto Medical Planning Company Profile 268
Table 150: Kyoto Medical Planning's Marketed Vascular Stent Product 270
Table 151: Kyoto Medical Planning SWOT Analysis, 2013 270
Table 152: Medtronic Company Profile 271
Table 153: Medtronic's Marketed Vascular Stent Products 272
Table 154: Medtronic SWOT Analysis, 2013 272
Table 155: Nexeon Stent Company Profile 273
Table 156: Nexeon Stent's Pipeline Vascular Stent Product 274
Table 157: Nexeon Stent SWOT Analysis, 2013 274
Table 158: Nipro Corporation Company Profile 275
Table 159: Nipro Corporation's Pipeline Vascular Stent Product 276
Table 160: Nipro Corporation SWOT Analysis, 2013 276
Table 161: NovoStent Corporation Company Profile 277
Table 162: NovoStent Corporation's Marketed Vascular Stent Product 278
Table 163: NovoStent Corporation SWOT Analysis, 2013 278
Table 164: OptiMed Company Profile 279
Table 165: OptiMed's Marketed Vascular Stent Products 280
Table 166: OptiMed SWOT Analysis, 2013 280
Table 167: Company Profile – PeriTec Biosciences 281
Table 168: PeriTec Bioscience's Pipeline Vascular Stent Product 282
Table 169: PeriTec Biosciences SWOT Analysis, 2013 282
Table 170: Synergy Flow Company Profile 283
Table 171: Pipeline Vascular Stent Product by Synergy Flow 283
Table 172: Synergy Flow SWOT Analysis, 2013 284
Table 173: Tepha Company Profile 285
Table 174: Tepha Medical Device's Pipeline Vascular Stent Product 286
Table 175: Tepha SWOT Analysis, 2013 286
Table 176: Terumo Corporation Company Profile 287
Table 177: Terumo Corporation's Marketed Vascular Stent Products 288
Table 178: Terumo Corporation SWOT Analysis, 2013 288
Table 179: TissueGen Company Profile 289
Table 180: TissueGen's Pipeline Vascular Stent Product 289
Table 181: TissueGen SWOT Analysis, 2013 290
Table 182: Translumina Company Profile 291
Table 183: Translumina's Pipeline Vascular Stent Product 292
Table 184: Translumina SWOT Analysis, 2013 292
Table 185: Vascular Concepts Company Profile 293
Table 186: Marketed Vascular Stent Products by Vascular Concepts 293
Table 187: Vascular Concepts SWOT Analysis, 2013 294
Table 188: Company Profile – Veryan Medical 295
Table 189: Marketed Vascular Stent Products by Veryan Medical 296
Table 190: Veryan Medical SWOT Analysis, 2013 296
Table 191: VueKlar Cardiovascular Company Profile 297
Table 192: VueKlar Cardiovascular's Pipeline Vascular Stent Product 298
Table 193: VueKlar Cardiovascular SWOT Analysis, 2013 298
Table 194: W.L. Gore & Associates Company Profile 299
Table 195: W.L. Gore & Associates' Marketed Vascular Stent Products 300
Table 196: W.L. Gore & Associates SWOT Analysis, 2013 300
Table 197: Zorion Medical Company Profile 301
Table 198: Pipeline Vascular Stent Products by Zorion Medical 301
Table 199: Zorion Medical SWOT Analysis, 2013 302
Table 200: Peripheral Vascular Stent Sales ($m) Forecast for France, 2010–2019 327
Table 201: Peripheral Vascular Stent Sales ($m) Forecast for Germany, 2010–2019 329
Table 202: Peripheral Vascular Stent Sales ($m) Forecast for Italy, 2010–2019 332
Table 203: Peripheral Vascular Stent Sales ($m) Forecast for Spain, 2010–2019 335
Table 204: Peripheral Vascular Stent Sales ($m) Forecast for UK, 2010–2019 338
Table 205: Physicians Surveyed, By Country 367

List of Figures

Figure 1: Peripheral Arteries of the Lower Extremity 28
Figure 2: Pathophysiology of Peripheral Artery Disease 30
Figure 3: Treatment Modalities – Peripheral Artery Disease 40
Figure 4: Percent of Patients with Peripheral Artery Disease Who Receive Each Therapy Option Only, EU, 2012 (n=25) 41
Figure 5: Treatment of PAD, EU*, 2012 and 2018 (n=25) 43
Figure 6: Types of Stents Used to Treat Peripheral Artery Disease 46
Figure 7: Bare Metal Stent For Treating Peripheral Artery Disease 46
Figure 8: Drug-Eluting Stent for Treating Peripheral Artery Disease 47
Figure 9: Covered Stents For Treating Peripheral Artery Disease 48
Figure 10: Types of Atherectomy 51
Figure 11: Prevalence of PAD in Population Age ?65 Years in the Major Markets in the EU, millions, 2010–2019 59
Figure 12: Healthcare Expenditures ($bn) for PAD in EU* 62
Figure 13: US Mean Hospital Costs* for Peripheral Revascularization Procedures, 2010–2019 64
Figure 14: EU* Peripheral Vascular Stent Market for Treating Peripheral Artery Disease in the Lower Extremity ($), 2012 65
Figure 15: EU* Peripheral Vascular Stent Market ($m) for Each Type of Artery, 2012 67
Figure 16: Remedy Stent for Treating Peripheral Artery Disease 172
Figure 17: Percent of PAD Patients With Restenosis After Stenting in the Peripheral Arteries in the Lower Extremity, EU*, 2012 (n=25) 181
Figure 18: Pipeline Peripheral Vascular Stent Products, 2013 186
Figure 19: Global Peripheral Vascular Stent Pipeline by Stage of Clinical Development, 2013 187
Figure 20: Population (? 65 years) with PAD Receiving Interventional Procedures for the Peripheral Arteries in the Lower Extremity, EU*, 2010–2019 217
Figure 21: Population (? 65 years) with PAD Receiving Stenting for the Peripheral Arteries in the Lower Extremity, EU*, 2010–2019 218
Figure 22: Global Peripheral Vascular Stent Market for Treating Peripheral Artery Disease in the Lower Extremity, Company Share (%), 2012 232
Figure 23: Global Peripheral Vascular Stent Market for Each Type of Artery, Company Share (%), 2012 234
Figure 24: Kyoto Medical Planning, Sales Volume ($m), May 2002–May 2012 269
Figure 25: Likelihood of Physician Adoption of Each Type of Vascular Stent in the Future for Treating Peripheral Artery Disease in the Lower Extremity, Global (n=50) 313
Figure 26: Importance of Each Attribute in Adopting Vascular Stents to Treat Peripheral Artery Disease in the Lower Extremity, Global, (n=50) 314
Figure 27: EU* Peripheral Vascular Stent Market ($m), 2010-2019 324
Figure 28: EU* Peripheral Vascular Stents Revenue ($m), 2012 and 2019 325
Figure 29: French Peripheral Vascular Stent Market ($m) for the Lower Extremity, 2010–2019 327
Figure 30: German Peripheral Vascular Stent Market ($m) for the Lower Extremity, 2010–2019 330
Figure 31: Italian Peripheral Vascular Stent Market ($m) for the Lower Extremity, 2010–2019 333
Figure 32: Spanish Peripheral Vascular Stent Market ($m) for the Lower Extremity, 2010–2019 335
Figure 33: UK Peripheral Vascular Stent Market ($m) for the Lower Extremity, 2010–2019 338

Companies Mentioned
Abbott Vascular
Amaranth Medical
Arterial Remodeling Technologies
Atrium Medical Corporation
Bard Peripheral Vascular (C.R. Bard)
Biotronik
Boston Scientific Corporation
3D Biotek
480 Biomedical
Cook Medical
Cordis Corporation (Johnson & Johnson

To order this report:
Surgical_Equipment Industry: MediPoint: Peripheral Vascular Stents for the Lower Extremity - EU Analysis and Market Forecasts

__________________________
Contact Clare: [email protected]
US:(339) 368 6001
Intl:+1 339 368 6001

SOURCE Reportlinker